Haemonetics Corporation (NYSE: HAE) surged 15.9% on Wednesday, extending gains to 91.88% since being flagged by an AI-driven stock-picking model in late 2025.
The advance follows the announcement of a multi-year supply agreement with CSL Plasma, under which Haemonetics will provide its NexSys PCS automated plasma collection systems with Persona PLUS technology to CSL’s U.S. collection centers. The deal marks a significant commercial validation for Haemonetics’ mid-tier plasma collection systems, which operate alongside the company’s higher-end NexSys PCS systems.
Shares of Haemonetics, which traded near $53.28 at the time of the AI model’s identification, closed at $53.28 on the day of publication, representing 56% of its 52-week high. The company’s valuation metrics included a price-to-earnings ratio of 14.9x and a PEG ratio of 0.34, alongside gross and operating margins of 58.8% and 19.4%, respectively. Year-over-year EBITDA growth reached 23.6%.
Haemonetics reported first-quarter revenue of $339.4 million, beating revenue estimates by 6.2%, while adjusted earnings per share of $1.14 exceeded expectations by 8.9%. Management maintained its full-year revenue growth guidance in a range of 5% to 8%.
The AI model, launched in November 2023, has delivered a cumulative return of 198.30% since inception, outperforming the S&P 500 by 116.67 percentage points. The engine processes 15 years of financial data across more than 150 quantitative models and applies machine learning to over 60,000 global equities. Haemonetics was classified under the Healthcare Heroes and Mid-Cap Movers strategies.
Wall Street’s consensus target for Haemonetics stands at $78, implying 46% upside from current levels, while the InvestingPro fair-value model projects a target of $76, suggesting 43% potential appreciation.
